AOD 9604 Peptide: What the Research Actually Shows

AOD 9604 is a 16-amino-acid fragment of human growth hormone, also called Tyr-hGH 177-191. It was designed to affect fat metabolism without raising IGF-1, but human weight-loss trials did not prove it worked better than placebo. It is not FDA-approved as a drug, and Chia does not currently offer it.

What is AOD 9604?

AOD 9604 is a small peptide based on the last part of human growth hormone. It was developed as a targeted way to study fat metabolism, not as a full growth-hormone replacement.

Origin as a growth hormone fragment

Human growth hormone, or hGH, is a larger protein made by the pituitary gland. AOD 9604 is based on hGH amino acids 176-191, with a tyrosine added at the start; this is why it is also called AOD 9604 (Tyr-hGH 177-191) 1.

The idea came from older research showing that the C-terminal, or tail end, of growth hormone seemed to carry some fat-metabolism signals. In animal work, the hGH 177-191 fragment reduced weight gain and fat mass in obese mice without causing the same growth effects seen with full growth hormone 2.

How it differs from full HGH

Full human growth hormone can raise IGF-1, affect fluid balance, and change glucose handling. AOD 9604 was designed to avoid those full-hormone effects while keeping a narrower fat-metabolism signal 1.

That design goal matters because full growth hormone has known risks, including swelling, joint pain, carpal tunnel symptoms, and changes in blood sugar. AOD 9604 was studied partly because researchers wanted a peptide that did not drive IGF-1 in the same way 1.

How does AOD 9604 work in the body?

AOD 9604 is proposed to change fat-cell behavior by increasing fat breakdown and reducing fat formation. The key point is that this mechanism is not the same as appetite suppression from GLP-1 medications.

Beta-3 adrenergic receptor activation

Some preclinical work links AOD 9604’s effects to the beta-3 adrenergic receptor, a receptor involved in fat-cell signaling and energy use. This proposed pathway is one reason AOD 9604 was studied for obesity rather than for growth-hormone deficiency 1.

Lipolysis vs. lipogenesis

Two words help explain the theory. Lipolysis means breaking stored fat into fatty acids. Lipogenesis means building and storing fat. AOD 9604 was investigated because lab and animal studies suggested it may increase lipolysis and reduce lipogenesis 1.

But a mechanism is not the same as a proven clinical result. Many compounds change fat-cell markers in the lab and still fail to cause meaningful weight loss in people. That is what makes the human trial results so important.

Why IGF-1 is not affected

IGF-1, or insulin-like growth factor 1, is one of the main downstream signals of full growth hormone. AOD 9604 was designed as a 16-amino-acid fragment, so it does not act like complete hGH in the body 1.

In the clinical program summarized by Heffernan, AOD 9604 was reported as well tolerated and did not show the same IGF-1 pattern expected from full growth hormone 1. That safety signal is useful, but it does not prove weight-loss efficacy.

What does the clinical evidence say about AOD 9604 for weight loss?

AOD 9604 has human data, but the key weight-loss finding is negative. Across the development program, it looked generally well tolerated, yet the pivotal obesity study did not show better weight loss than placebo.

The six Phase I/II trials

Metabolic Pharmaceuticals developed AOD 9604 as an anti-obesity drug candidate. A later clinical summary describes six Phase I/II studies with about 900 participants exposed to AOD 9604, including studies that looked at safety, pharmacokinetics, and weight outcomes 1.

Those early trials matter because they suggest the peptide did not show a major short-term safety signal in the studied population. They also show the limits of early-phase research: tolerability can look acceptable while efficacy remains uncertain.

METAOD005 12-week results

In the 12-week METAOD005 trial, oral AOD 9604 was studied in adults with obesity. The study explored several oral doses and reported weight-loss signals at some doses, but the response was not strong enough to settle the question 1.

This is a common pattern in drug development. A dose-finding study may show a possible signal, but the next larger study must prove the effect is real, consistent, and clinically useful.

Why the pivotal Phase IIb trial failed

The larger METAOD006 Phase IIb trial was designed to test whether the earlier signal held up. It did not: AOD 9604 failed to show statistically significant weight loss compared with placebo, and development for obesity was halted in 2007 1.

That does not mean every future study would be impossible. It means that, based on the available human obesity program, AOD 9604 does not have the kind of weight-loss evidence we would expect before using it as a main obesity medication.

Development halted in 2007

The halt in development is important context for patients reading online claims. AOD 9604 is often marketed with strong fat-loss language, but the best human obesity trial did not confirm those claims 1.

Individual results can vary in any study. Still, when a larger randomized trial does not beat placebo, we treat the peptide as investigational rather than established for weight loss.

Is AOD 9604 FDA-approved?

AOD 9604 is not FDA-approved as a drug for weight loss or any other medical condition. A separate food-ingredient safety pathway is sometimes confused with drug approval, but those are not the same thing.

Drug status vs. GRAS food-ingredient designation

The FDA has a GRAS, or “generally recognized as safe,” process for certain food ingredients. AOD 9604 has been discussed in that food-ingredient context, but a GRAS notice is not an FDA drug approval and does not prove that a product works for weight loss 3.

FDA drug approval is a different standard. It requires evidence that a specific drug product is safe and effective for a labeled use, with manufacturing and labeling reviewed by the agency 4.

Research-use and compounded-peptide realities

Many AOD 9604 products online are sold as “research” peptides or through channels that may not include a licensed medical evaluation. That is a safety problem because purity, sterility, identity, and patient-specific risks may not be reviewed.

The safer axis is licensed care versus unlicensed sourcing. When a medication is prescribed, a licensed clinician reviews health history and a state-licensed pharmacy is responsible for compounding and dispensing under applicable rules 5.

How is AOD 9604 typically dosed and administered?

AOD 9604 dosing advice online is often not based on FDA labeling because there is no FDA-approved AOD 9604 drug label. Published obesity development focused on oral study protocols, while many current commercial protocols discuss injections.

Subcutaneous injection

Subcutaneous injection means an injection into the fatty layer under the skin. Many peptide clinics discuss AOD 9604 this way, but that should not be confused with an FDA-approved dosing route or a proven weight-loss protocol.

Because AOD 9604 is not FDA-approved as a drug, there is no FDA-reviewed prescribing information that tells clinicians and patients a standard dose, schedule, route, contraindication list, or monitoring plan.

Timing and fasted-state rationale

Some online protocols suggest fasting around AOD 9604 because the proposed target is fat mobilization. That idea is mechanistic, not proof of clinical benefit. A timing theory should not be treated as a patient instruction.

What research protocols used

In the obesity trials summarized by Heffernan, AOD 9604 was studied as oral therapy, including a 12-week dose-finding trial and a later Phase IIb trial 1. Any dose numbers from those trials describe research conditions, not instructions for readers.

If you are considering any peptide, bring the exact product, route, dose claim, and source to a licensed clinician. This is especially important if you take diabetes medications, have a history of cancer, are pregnant, or have endocrine conditions.

Is AOD 9604 safe? Known side effects

AOD 9604 looked generally well tolerated in the human studies summarized to date, but the safety database is limited compared with FDA-approved obesity medications. Lack of a major short-term signal is not the same as proven long-term safety.

Findings from about 900-participant safety data

Across about 900 study participants, the published clinical summary reported that AOD 9604 was well tolerated and did not show the growth-hormone-like effects researchers were trying to avoid, such as IGF-1 elevation 1.

Possible side effects discussed in peptide practice can include injection-site irritation, headache, nausea, or fluid-related symptoms, but the exact risk depends on product quality, route, dose, health history, and other medications.

What we do not yet know

We do not have large, modern, long-term randomized trials showing that AOD 9604 improves weight, heart outcomes, diabetes outcomes, or body composition in a durable way. We also do not have FDA-reviewed labeling that defines contraindications or monitoring.

That uncertainty matters. A peptide can be biologically interesting and still not be the right clinical tool for weight management.

How does AOD 9604 compare with GLP-1 medications like semaglutide and tirzepatide?

AOD 9604 targets fat-cell metabolism in theory, while semaglutide and tirzepatide act through gut-hormone pathways that affect appetite, fullness, and glucose regulation. The evidence base is much stronger for the active ingredients semaglutide and tirzepatide as studied in large randomized trials.

Semaglutide is the active ingredient in Wegovy and Ozempic and is a GLP-1 receptor agonist; it is also available as a compounded formulation through licensed 503A pharmacies, including compounded semaglutide at Chia. Tirzepatide is the active ingredient in Mounjaro and Zepbound and is a GIP/GLP-1 receptor agonist; Chia offers compounded tirzepatide tablets and injections. Compounded formulations are not FDA-approved and do not have FDA-evaluated outcomes data.

Mechanism: lipolysis vs. appetite suppression

The practical difference is simple. AOD 9604 was built around fat-cell signaling. GLP-1-based medications act on hormone receptors that help regulate hunger, fullness, gastric emptying, and blood sugar 7.

Strength of evidence

AOD 9604’s key obesity trial did not show a clear weight-loss benefit over placebo 1. By contrast, the active ingredients semaglutide and tirzepatide have been studied in large randomized trials, though compounded formulations have not been evaluated by FDA for safety or effectiveness 6, 8.

Regulatory status

AOD 9604 has no FDA-approved drug label. Semaglutide and tirzepatide each have FDA-approved drug products for specific uses, while compounded semaglutide and compounded tirzepatide are prescribed under the compounding framework and are not FDA-approved 5, 7, 9.

Who each may suit

For a patient focused on evidence-based weight-loss medication, a clinician will often start by reviewing GLP-1-pathway options, health history, contraindications, goals, and side-effect risk. For a patient drawn to AOD 9604 because of the growth-hormone-axis idea, the more useful discussion may be what is actually being targeted: fat loss, appetite, energy, recovery, sleep, or body composition.

If you are considering peptides for weight loss, what evidence-based options can Chia evaluate?

Chia does not currently offer AOD 9604. We can evaluate eligible patients for compounded GLP-1 treatment and certain longevity peptides we actually offer, using an online visit reviewed by a licensed US provider.

Why Chia does not offer AOD 9604 today

We do not offer AOD 9604 because it is not FDA-approved as a drug and its main obesity development program did not prove weight-loss benefit over placebo 1. That does not make every AOD 9604 discussion unsafe or unserious, but it does mean we treat it as education-only.

Compounded semaglutide and tirzepatide, including microdosing

At Chia, compounded semaglutide is available as an injection, with microdosing plans available when clinically appropriate. Plans currently start at $249/mo, and the product page has current details.

Chia also offers compounded tirzepatide as tablets and injections, with microdosing plans available. Tirzepatide tablets currently start at $249/mo, and tirzepatide injections currently start at $299/mo.

Sermorelin for growth-hormone-axis support

For patients who found AOD 9604 while researching growth-hormone biology, sermorelin may be a more relevant Chia conversation than AOD 9604. Sermorelin is a GHRH analog, meaning it signals the pituitary to release growth hormone in a more upstream way.

Sermorelin is not a primary obesity medication. Side effects can include injection-site reactions, flushing, headache, dizziness, or changes that matter for people with glucose or endocrine conditions, so eligibility needs a clinician review.

The Weight + Energy and GLP-1 + Sermorelin protocols

Some patients want weight-loss care plus support for energy or the growth-hormone axis. Chia’s Weight + Energy protocol includes NAD+ injection with a choice of GLP-1, and our GLP-1 + Sermorelin protocol combines sermorelin injection with a choice of GLP-1.

Here is how treatment works at Chia: you complete a short online health questionnaire, a licensed US provider reviews it, and medication is prescribed only if clinically appropriate. When prescribed, medications are compounded by US state-licensed 503A pharmacies and shipped to your door. Dosing is provider-guided and can be adjusted over time through the patient portal.

How should you talk to a clinician about peptide therapy?

Bring the exact peptide name, source, route, claimed dose, and your goals. A good visit should cover evidence, side effects, contraindications, lab history, other medications, and whether the product comes through a licensed pharmacy.

For AOD 9604, the key questions are not just “does it burn fat?” but “what human trial proves that?” and “who is responsible for product quality?” The published answer on weight loss is weak, and the product-quality question depends heavily on sourcing 1, 5.

• Ask what outcome the peptide is meant to support: appetite, fat mass, waist size, energy, recovery, sleep, or labs.
• Review medical history, including pregnancy plans, cancer history, endocrine disorders, gallbladder disease, pancreatitis, diabetes medications, and kidney or liver disease.
• Avoid no-prescription “research chemical” products for self-use; a licensed provider and state-licensed pharmacy add important safety checks.
• Separate mechanism from proof. A pathway can be interesting even when clinical outcomes are not established.
• If comparing options, ask how side effects and contraindications differ, not just how much weight a trial reported.

What is the bottom line on AOD 9604?

AOD 9604 is an interesting growth-hormone fragment with a clean theory and disappointing obesity-trial results. The pivotal trial did not prove weight loss beyond placebo, and the peptide is not FDA-approved as a drug.

If your real goal is medical weight-loss care, it is more useful to talk with a licensed clinician about options with stronger human evidence, clear safety screening, and pharmacy oversight. At Chia, that may include compounded semaglutide, compounded tirzepatide, sermorelin, or a protocol that combines eligible therapies, depending on your evaluation.

Keep reading

Peptides

AOD-9604 Peptide: What It Is, How It Works, and What the Evidence Shows

Peptides

Peptide Injections: What They Are, How They Work, and What to Expect

GLP-1 & Weight Loss

Reta Peptide (Retatrutide): How the Triple-Receptor GLP-1/GIP/Glucagon Agonist Works